Showing results (1281-1290 of 1,376) with videos related to

Sort By:
Pageof 138
Proceedings of the National Academy of Sciences of the United States of America|November 10, 2010
Robust crop resistance to broadleaf and grass herbicides provided by aryloxyalkanoate dioxygenase transgenesTerry R Wright, Guomin Shan, Terence A Walsh, et al.
Therapeutic Advances in Neurological Disorders|May 26, 2021
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trialAlasdair J Coles, Douglas L Arnold, Ann D Bass, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 23, 2010
Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studiesMarcelo C Pasquini, Linda M Griffith, Douglas L Arnold, et al.
Journal of Neurology|May 31, 2022
Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND studyRalf Gold, Daniela Piani-Meier, Ludwig Kappos, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 6, 2020
Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIGMS studyDouglas L Arnold, Brenda Banwell, Amit Bar-Or, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|July 8, 2020
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS studyTanuja Chitnis, Brenda Banwell, Lauren Krupp, et al.
Journal of Community Genetics|May 25, 2013
How do researchers manage genetic results in practice? The experience of the multinational Colon Cancer Family RegistryLouise A Keogh, Douglass Fisher, Sherri Sheinfeld Gorin, et al.
Frontiers in Microbiology|January 2, 2025
The fungal gut microbiota in pediatric-onset multiple sclerosisNelson Mok, Natalie C Knox, Feng Zhu, et al.
Pageof 138